Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Summit Therapeutics PLC (NASDAQ:SMMT)

11.88
Delayed Data
As of 2:13pm ET
 +1.19 / +11.10%
Today’s Change
7.95
Today|||52-Week Range
16.86
+38.79%
Year-to-Date
No recent news for Summit Therapeutics PLC.

Today’s Trading

Previous close10.69
Today’s open10.96
Day’s range10.80 - 11.88
Volume68,728
Average volume (3 months)35,451
Market cap$150.9M
Dividend yield--
Data as of 2:13pm ET, 11/20/2017

Growth & Valuation

Earnings growth (last year)-5.90%
Earnings growth (this year)+77.56%
Earnings growth (next 5 years)--
Revenue growth (last year)+166.82%
P/E ratioNM
Price/Sales46.76
Price/Book--

Competitors

 Today’s
change
Today’s
% change
MLNTMelinta Therapeutics...-0.40-2.91%
ACRXAcelRx Pharmaceutica...+0.05+2.41%
PPHMPeregrine Pharmaceut...-0.05-1.14%
RDHLRedhill Biopharma Lt...+0.04+0.73%
Data as of 2:31pm ET, 11/20/2017

Financials

Next reporting dateDecember 14, 2017
EPS forecast (this quarter)-$0.40
Annual revenue (last year)$3.1M
Annual profit (last year)-$28.5M
Net profit margin-922.36%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Executive Director
Glyn O. Edwards
Chief Operating &
Medical Officer
David Roblin
Corporate headquarters
Abingdon, Oxfordshire

Forecasts